Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab. Issue 4 (December 2015)

• Record Type: Journal Article
• Authors: Ly, K. Ina; Hamilton, Steven R.; Rostomily, Robert C.; Rockhill, Jason K.; Mrugala, Maciej M.
• Is Part Of: Journal of neuro-ophthalmology. Volume 35:Issue 4(2015:Dec.)
• Publication Date: 2015-12
• Subjects: Neuroophthalmology -- Periodicals; 617.7
• DOI: 10.1097/WNO.0000000000000253
• Languages: English
• ISSNs: 1070-8022

Abstract

Abstract : Abstract: High-grade (World Health Organization [WHO] Grade II and III) meningiomas constitute a minority of all meningioma cases but are associated with significant morbidity and mortality, due to more aggressive tumor behavior and a tendency to recur despite standard therapy with resection and radiotherapy. They display a higher degree of vascularity than WHO Grade I meningiomas and produce angiogenic and growth factors, including vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF-A, has been used in the treatment of recurrent or progressive meningiomas resistant to standard therapy. We report a patient with a recurrent left frontotemporal meningioma and associated-vision loss who experienced substantial visual field recovery after 3 cycles of bevacizumab. In addition, we provide a review of the literature regarding the efficacy of bevacizumab in the treatment of recurrent meningiomas. Abstract : Supplemental Digital Content is Available in the Text.